Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04280055
Other study ID # H-18040896
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date January 21, 2020
Est. completion date June 1, 2022

Study information

Verified date August 2022
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the prophylactic effects of psilocybin in chronic cluster headache. Subjects will receive a low dose of psilocybin during 3 sessions spaced by one week. Subjects will maintain a headache diary prior to, during, and after the administrations in order to document headache frequency, intensity and duration. Subjects will undergo a fMRI scanning before the first and after the last psilocybin session.


Description:

Cluster headache (CH) is one of the most painful conditions known. CH affects 1 out 1000 and exists in two well-defined forms: episodic (ECH) and chronic (CCH). Ten to fifteen percent of patients have CCH and have less than three months of pain-free time during a year. Medical treatment for CH is divided into acute abortive treatment for the single attack and a prophylactic treatment. The most commonly used prophylactic, verapamil, decreases attack frequency but does not induce remission and very high doses are needed. Although most therapeutic options ameliorate CH, they may be problematic due to major side effects, unsatisfactory treatment response or availability. Thus, novel treatment options are needed. According to several studies, patients that self-medicate with low doses of the serotonin 2A receptor (5-HT2AR) agonist and psychedelic psilocybin report that this is effective as CH prophylaxis or even to induce remission. So far, no clinical trials to confirm this have been conducted, nor is there any objective measures of brain function in association with psilocybin intake in CH. There is, however, already some evidence from functional magnetic resonance (fMRI) imaging studies suggesting that CH patients have abnormal functional connectivity patterns involving the hypothalamus and distributed brain networks, but the implication of these abnormalities is unknown. The investigators are conducting a prospective pilot study, evaluating prophylactic effects of psilocybin in CCH using an open-label study design. They're also going to investigate psilocybin's active metabolite psilocin and brain function (fMRI) to identify possible brain mechanisms underlying CCH and treatment response, including the correlation of treatment response with psilocin levels and estimated 5-HT2AR occupancy and the extent to which brain network changes are affected by psilocybin and correlated with treatment response. Effects of psilocybin on headache frequency, duration and intensity will be assessed in a sample of 20 patients with CCH. Participants will fill out headache logs during the entire study period, in total 10 weeks. Before study inclusion, participants taking prophylactic medication will first go through a 2-week wash-out period to allow for elimination of the medicine. Inclusion is followed by a baseline observation period lasting four weeks, after which patients will first undergo a baseline rs fMRI scanning followed by the first dose of 0.14 mg/kg psilocybin p.o. Blood samples will be collected during the first psilocybin intervention to establish psilocin plasma concentrations, which will be used for estimating receptor occupancy. Participants will then undergo two additional psilocybin administrations spaced by one-week. The last psilocybin dose will be followed by 4 weeks of observation. One week after the last administration of psilocybin, participants will undergo a follow-up MRI scan. Participants will be contacted 3, 6 and 12 months after the last psilocybin dose to gain information about the duration of potential remission periods. All regular acute treatments are permitted during the study period and a systematic record hereof has to be noted in the headache diary. No other prophylactic medication is allowed during the trial and at least a two-week washout period before inclusion is required. Prophylactics are allowed again after the 4 weeks follow-up, with dose and type carefully recorded. Participants will fill out questionnaires during the observation period, in conjunction with psilocybin interventions and at follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date June 1, 2022
Est. primary completion date November 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age between 18 and 65 - A diagnosis of chronic cluster headache according to IHCD-III. - Ability to separate cluster headache attacks from other types of headache. - A history of at least 4 attacks/week in the last 4 weeks before inclusion Exclusion Criteria: - A history of using a serotonergic hallucinogen for CH. - Participation in any clinical trials within 30 days preceding study enrollment. - Use of other prophylactic CH medication within the last two weeks. - Current use of drugs suspected to interfere with treatment (e.g. antipsychotic medication) or to be hazardous in combination with psilocybin. - Presence of other trigeminal autonomic cephalalgias. - Known hypersensitivity/allergy to multiple drugs (including psilocybin). - A history or presence of any medical and psychiatric condition that might render patient unsuitable for participation. - Present or previous manic or psychotic disorder or critical psychiatric disorder. - Current drug or alcohol abuse. - MRI Contraindications. - Pregnancy or breastfeeding - Not using safe contraception (if fertile woman) - Stroke (<1 year from inclusion) - Myocardial infarction (<1 year from inclusion) - Hypertension (> 140/90 mmHg at inclusion) - Clinically significant arrhythmia (<1 year from inclusion)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Psilocybin
0.14 mg/kg p.o. in three sessions spaced by one week

Locations

Country Name City State
Denmark Neurobiology Research Unit, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Gitte Moos Knudsen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Headache frequency Change in headache frequency in number of attacks/week Week 6-10 (post drug observation) compared to week 0-4 (baseline observation)
Primary Resting state FC fMRI analyses Resting state FC fMRI analyses, including hypothalamic FC, comparing baseline and rescan, comparison with healthy control sample, and evaluation of correlation between headache frequency changes and FC changes. Day 1 of first psilocybin session to 1 week after last psilocybin session (3 weeks)
Secondary Proportion of reduced frequency Proportion of patients with a 50% reduction in headache frequency Week 6-10 (post drug observation) compared to week 0-4 (baseline observation)
Secondary Headache intensity Change in average headache intensity of attacks (0-10 on Visual Analog Scale (VAS), where 0 is no pain and 10 is worst pain imaginable) Week 6-10 (post drug observation) compared to week 0-4 (baseline observation)
Secondary Need of acute therapy Number of attacks requiring acute therapy Week 6-10 (post drug observation) compared to week 0-4 (baseline observation)
Secondary Sideeffects Proportion of patients experiencing serious side effects Whole observation period (10 weeks)
Secondary Remission Proportion of patients with remission lasting more than 1 month Day 1 after first psilocybin session until 12 month follow up (1 year).
Secondary Remission duration Duration of induced remission (number of weeks) Day 1 after first psilocybin session until 12 month follow up (1 year).
Secondary SF-36 Quality of life assessed by questionnaires: The Short Form (36) Health Survey. SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. Week 6-10 (post drug observation) compared to week 0-4 (baseline observation)
Secondary Preferred treatment Proportion of patients that prefers to continue with psilocybin if this was an option or want to return to usual prophylactics. Whole observation period (10 weeks)
Secondary Mood Changes in mood measured be the POMS questionaire. Pre-psilocybin (week 1 and 5) vs post-psilocybin (week six and eight).
Secondary Sleep quality Sleep quality measured by the PSQI questionaire. Pre-psilocybin (week 1 and 5) vs post-psilocybin (week six and eight).
Secondary Depressive symptoms Depressive symptoms measured by the MDI questionaire. Pre-psilocybin (week 1 and 5) vs post-psilocybin (week six and eight).
Secondary Stress Perceived stress measured by the PSS questionaire. Pre-psilocybin (week 1 and 5) vs post-psilocybin (week six and eight).
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2